76 completed, 9 recruiting, 7 terminated, 2 not yet recruiting. 99 Phase 3, 10 Phase 2.
Follow Keratosis: new trials by email Literature Review of Keratosis trials Research Report on Keratosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead Cryotherapy + Tirbanibulin - Keratosis, Actinic Keratoses | Phase 3 | Not yet recruiting | University Hospital, Lille | 59 | 2026-11-30 | 2026-05-22 |
| Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis Clinical decision support tool - Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 14000 | 2026-10-15 | 2026-10-22 |
| Basal Cell Carcinoma Chemoprevention Trial 5% Imiquimod cream, Placebo Vehicle Control Cream - Basal Cell Carcinoma | Phase 3 | Recruiting | VA Office of Research and Development | 1630 | 2026-10-06 | 2026-11-02 |
| Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome) Chang Ji'an capsule, Chang Ji'an capsule mimic - IBS, Diarrhea Predominant | Phase 3 | Not yet recruiting | Beijing Hospital of Traditional Chinese Medicine | 636 | 2026-05-31 | 2026-05-28 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E. - Actinic Keratosis | Phase 3 | Recruiting | Sun Pharmaceutical Industries, Inc. | 260 | 2025-11-29 | 2026-11-04 |
| Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E - Actinic Keratosis | Phase 3 | Recruiting | Sun Pharmaceutical Industries, Inc. | 160 | 2025-11-19 | 2026-11-04 |
| Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome Saccharomyces Boulardii 250 MG, Placebo 250 mg - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 3 | Recruiting | Biocodex | 406 | 2025-10-22 | 2025-11-18 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis Topical treatment - Actinic Keratosis of Face and Scalp | Phase 3 | Recruiting | Aresus Pharma GmbH | 280 | 2024-09-04 | 2025-08-22 |
| A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis Tirbanibulin, Vehicle ointment - Keratosis, Actinic | Phase 3 | Completed | Almirall, S.A. | 280 | 2023-12-21 | 2026-06-30 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp - Actinic Keratoses | Phase 3 | Completed | Biofrontera Inc. | 172 | 2022-12-12 | 2026-08-21 |
| A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis Tirbanibulin ointment 1% - Keratosis, Actinic | Phase 3 | Completed | Almirall, S.A. | 105 | 2022-06-28 | 2024-01-23 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis TMB-001, Matching Vehicle - Ichthyosis | Phase 3 | Completed | LEO Pharma | 153 | 2022-06-21 | 2026-05-22 |
| Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India - Actinic Keratoses | Phase 3 | Completed | Encube Ethicals Pvt. Ltd. | 458 | 2022-03-01 | 2023-03-14 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp KX01 ointment 1%, Placebo - Actinic Keratosis | Phase 3 | Completed | PharmaEssentia | 108 | 2021-12-21 | 2024-04-19 |
| 5% KOH Solution vs. Placebo and Diclofenac Gel for the Treatment of Actinic Keratosis Solcera, Placebo, Solaraze - Actinic Keratosis | Phase 3 | Completed | Infectopharm Arzneimittel GmbH | 631 | 2020-10-14 | 2024-03-05 |
Showing 20 of 99. Sign in to see all of them.
Keratosis, Actinic (78) · Precancerous Conditions (8) · Skin Diseases (8) · Netherton Syndrome (6) · Carcinoma, Squamous Cell (5) · Keratosis, Seborrheic (4) · Carcinoma, Basal Cell (3) · Ichthyosis Bullosa of Siemens (3) · Neoplasms (3) · Foot Dermatoses (2) · Ichthyosis (2) · Ichthyosis, Lamellar (2) · Keratoderma, Palmoplantar, Epidermolytic (2) · Nails, Malformed (2)
Skin and Connective Tissue Diseases (99) · Skin Diseases (91) · Neoplasms (76) · Precancerous Conditions (70) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Congenital Abnormalities (14) · Genetic Diseases, Inborn (14) · Infant, Newborn, Diseases (14) · Skin Abnormalities (14) · Skin Diseases, Genetic (14) · Ichthyosis (12) · Ichthyosiform Erythroderma, Congenital (8) · Neoplasms by Histologic Type (7) · Abnormalities, Multiple (6)
3-ingenyl angelate (11) · Aminolevulinic Acid (7) · Photochemotherapy (7) · Imiquimod (6) · Fluorouracil (5) · methyl 5-aminolevulinate (5) · Diclofenac (4) · Gels (4) · Solutions (4) · BF-200 ALA (3) · Cryotherapy (3) · Therapeutics (2) · tirbanibulin (2) · 1-phenyl-3,3-dimethyltriazene (1) · 5-fluorouracil, salicylic acid drug combination (1)
LEO Pharma (10) · Almirall, S.A. (7) · Galderma R&D (7) · Actavis Inc. (6) · Peplin (5) · Quoin Pharmaceuticals (4) · Aclaris Therapeutics, Inc. (3) · Biofrontera Bioscience GmbH (3) · Graceway Pharmaceuticals, LLC (3) · DUSA Pharmaceuticals, Inc. (2) · Encube Ethicals Pvt. Ltd. (2) · Padagis LLC (2) · Pfizer (2) · Sun Pharmaceutical Industries, Inc. (2) · Teva Pharmaceuticals USA (2)
United States (59) · Germany (20) · France (11) · Canada (8) · United Kingdom (8) · Australia (7) · Italy (5) · Netherlands (5) · Spain (4) · Sweden (3) · Switzerland (3) · Brazil (2) · China (2) · Denmark (2) · Japan (2)
Stuart D Shanler, MD (3) · C. William Hanke, MD (2) · Edward Maytin, MD, PhD (2) · Eugene Bauer, MD (2) · Jane Fang, MD (2) · Sharon F Levy, MD (2) · Stuart Marcus, MD, PhD (2) · Tony Andrasfay (2) · Ann-Marie Wennberg, MD, PhD (1) · Axel Hauschild, Professor MD (1) · Bibiana Perez Garcia, MD (1) · Brian Berman, MD, Ph.D (1)
PMID 22417254, PMID 30365590, PMID 33567191, PMID 20133013, PMID 20518784, PMID 21115882, PMID 21866055, PMID 23252768, PMID 24102348, PMID 24509965, PMID 24918567, PMID 26300464, PMID 27995485, PMID 31299087, PMID 31955461, PMID 38125671, PMID 39666443, PMID 40996107
2005 (1), 2014 (1), 2017 (1), 2023 (1), R01CA293974 (1), R21CA156227 (1), U01HD040657 (1)